Asset Management One Co. Ltd. Purchases 9,237 Shares of DexCom, Inc. $DXCM

Asset Management One Co. Ltd. raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 264,022 shares of the medical device company’s stock after buying an additional 9,237 shares during the quarter. Asset Management One Co. Ltd.’s holdings in DexCom were worth $17,766,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in DXCM. Brighton Jones LLC increased its stake in DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after acquiring an additional 11,946 shares during the period. Advisors Asset Management Inc. lifted its stake in DexCom by 6.1% during the first quarter. Advisors Asset Management Inc. now owns 12,674 shares of the medical device company’s stock worth $866,000 after purchasing an additional 726 shares during the period. Integrated Wealth Concepts LLC boosted its holdings in DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares in the last quarter. UniSuper Management Pty Ltd grew its stake in shares of DexCom by 6.2% in the 1st quarter. UniSuper Management Pty Ltd now owns 40,554 shares of the medical device company’s stock valued at $2,769,000 after purchasing an additional 2,377 shares during the period. Finally, Dynamic Technology Lab Private Ltd raised its holdings in shares of DexCom by 17.0% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 4,680 shares of the medical device company’s stock worth $320,000 after buying an additional 681 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on DXCM shares. Mizuho boosted their price target on DexCom from $75.00 to $78.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Barclays set a $80.00 price objective on DexCom and gave the company an “equal weight” rating in a report on Monday, November 3rd. Cowen restated a “buy” rating on shares of DexCom in a research note on Friday, October 24th. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. Finally, Morgan Stanley upgraded shares of DexCom from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $63.00 to $75.00 in a research report on Tuesday, December 2nd. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $86.61.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach purchased 18,200 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were acquired at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the purchase, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 7,866 shares of company stock worth $448,177. Corporate insiders own 0.32% of the company’s stock.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $67.65 on Tuesday. The business has a fifty day moving average of $63.68 and a 200-day moving average of $72.40. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $93.25. The firm has a market cap of $26.38 billion, a PE ratio of 37.58, a price-to-earnings-growth ratio of 1.20 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.04. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The firm’s quarterly revenue was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.45 EPS. On average, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.